Nancy Babio1, Estefanía Toledo1, Ramón Estruch1, Emilio Ros1, Miguel A Martínez-González1, Olga Castañer1, Mònica Bulló1, Dolores Corella1, Fernando Arós1, Enrique Gómez-Gracia1, Valentina Ruiz-Gutiérrez1, Miquel Fiol1, José Lapetra1, Rosa M Lamuela-Raventos1, Lluís Serra-Majem1, Xavier Pintó1, Josep Basora1, José V Sorlí1, Jordi Salas-Salvadó1. 1. Human Nutrition Unit (Babio, Bulló, Basora, Salas-Salvadó), Faculty of Medicine and Health Sciences, Biochemistry Biotechnology Department, Universitat Rovira i Virgili, and Hospital Universitari de Sant Joan de Reus, IISPV, Reus, Spain; Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición (CIBERobn) (Babio, Toledo, Estruch, Martínez-González, Castañer, Bulló, Corella, Arós, Gómez-Gracia, Ruiz-Gutiérrez, Fiol, Lapetra, Lamuela-Raventos, Serra-Majem, Pintó, Basora, Sorlí, Salas-Salvadó), Institute of Health Carlos III, Madrid, Spain; Department of Preventive Medicine and Public Health (Toledo, Martínez-González), University of Navarra, Pamplona, Spain; Department of Internal Medicine (Estruch), Institut d'Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Hospital Clínic, University of Barcelona, Barcelona, Spain; Lipid Clinic (Ros), Endocrinology and Nutrition Service, IDIBAPS, Hospital Clinic, University of Barcelona, Barcelona, Spain; Cardiovascular Risk and Nutrition Research Group (Castañer), Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona Biomedical Research Park, Barcelona, Spain; Department of Preventive Medicine (Corella, Sorlí), University of Valencia, València, Spain; Department of Cardiology (Arós), University Hospital Txagorritxu, Vitoria, Spain; Department of Preventive Medicine (Gómez-Gracia), University of Malaga, Malaga, Spain; Instituto de la Grasa (Ruiz-Gutiérrez), Consejo Superior de Investigaciones Cientificas, Seville; Instituto de Investigación Sanitaria de Palma (Fiol), Hospital Universitario Son Espases, Mallorca; Department of Family Medicine (Lapetra), Primary Care Division of Seville, San Pablo Health Center, Seville; Department of Nutrition and Food Science (Lamuela-Raventos), School of Pharmacy, Xarxa de Referència en Tecnologia dels Aliments, Instituto de Investigación en Nutrición y Seguridad Alimentaria, University of Barcelona, Barcelona, Spain; De
Abstract
BACKGROUND: Little evidence exists on the effect of an energy-unrestricted healthy diet on metabolic syndrome. We evaluated the long-term effect of Mediterranean diets ad libitum on the incidence or reversion of metabolic syndrome. METHODS: We performed a secondary analysis of the PREDIMED trial--a multicentre, randomized trial done between October 2003 and December 2010 that involved men and women (age 55-80 yr) at high risk for cardiovascular disease. Participants were randomly assigned to 1 of 3 dietary interventions: a Mediterranean diet supplemented with extra-virgin olive oil, a Mediterranean diet supplemented with nuts or advice on following a low-fat diet (the control group). The interventions did not include increased physical activity or weight loss as a goal. We analyzed available data from 5801 participants. We determined the effect of diet on incidence and reversion of metabolic syndrome using Cox regression analysis to calculate hazard ratios (HRs) and 95% confidence intervals (CIs). RESULTS: Over 4.8 years of follow-up, metabolic syndrome developed in 960 (50.0%) of the 1919 participants who did not have the condition at baseline. The risk of developing metabolic syndrome did not differ between participants assigned to the control diet and those assigned to either of the Mediterranean diets (control v. olive oil HR 1.10, 95% CI 0.94-1.30, p = 0.231; control v. nuts HR 1.08, 95% CI 0.92-1.27, p = 0.3). Reversion occurred in 958 (28.2%) of the 3392 participants who had metabolic syndrome at baseline. Compared with the control group, participants on either Mediterranean diet were more likely to undergo reversion (control v. olive oil HR 1.35, 95% CI 1.15-1.58, p < 0.001; control v. nuts HR 1.28, 95% CI 1.08-1.51, p < 0.001). Participants in the group receiving olive oil supplementation showed significant decreases in both central obesity and high fasting glucose (p = 0.02); participants in the group supplemented with nuts showed a significant decrease in central obesity. INTERPRETATION: A Mediterranean diet supplemented with either extra virgin olive oil or nuts is not associated with the onset of metabolic syndrome, but such diets are more likely to cause reversion of the condition. An energy-unrestricted Mediterranean diet may be useful in reducing the risks of central obesity and hyperglycemia in people at high risk of cardiovascular disease. TRIAL REGISTRATION: ClinicalTrials.gov, no. ISRCTN35739639.
RCT Entities:
BACKGROUND: Little evidence exists on the effect of an energy-unrestricted healthy diet on metabolic syndrome. We evaluated the long-term effect of Mediterranean diets ad libitum on the incidence or reversion of metabolic syndrome. METHODS: We performed a secondary analysis of the PREDIMED trial--a multicentre, randomized trial done between October 2003 and December 2010 that involved men and women (age 55-80 yr) at high risk for cardiovascular disease. Participants were randomly assigned to 1 of 3 dietary interventions: a Mediterranean diet supplemented with extra-virgin olive oil, a Mediterranean diet supplemented with nuts or advice on following a low-fat diet (the control group). The interventions did not include increased physical activity or weight loss as a goal. We analyzed available data from 5801 participants. We determined the effect of diet on incidence and reversion of metabolic syndrome using Cox regression analysis to calculate hazard ratios (HRs) and 95% confidence intervals (CIs). RESULTS: Over 4.8 years of follow-up, metabolic syndrome developed in 960 (50.0%) of the 1919 participants who did not have the condition at baseline. The risk of developing metabolic syndrome did not differ between participants assigned to the control diet and those assigned to either of the Mediterranean diets (control v. olive oil HR 1.10, 95% CI 0.94-1.30, p = 0.231; control v. nuts HR 1.08, 95% CI 0.92-1.27, p = 0.3). Reversion occurred in 958 (28.2%) of the 3392 participants who had metabolic syndrome at baseline. Compared with the control group, participants on either Mediterranean diet were more likely to undergo reversion (control v. olive oil HR 1.35, 95% CI 1.15-1.58, p < 0.001; control v. nuts HR 1.28, 95% CI 1.08-1.51, p < 0.001). Participants in the group receiving olive oil supplementation showed significant decreases in both central obesity and high fasting glucose (p = 0.02); participants in the group supplemented with nuts showed a significant decrease in central obesity. INTERPRETATION: A Mediterranean diet supplemented with either extra virgin olive oil or nuts is not associated with the onset of metabolic syndrome, but such diets are more likely to cause reversion of the condition. An energy-unrestricted Mediterranean diet may be useful in reducing the risks of central obesity and hyperglycemia in people at high risk of cardiovascular disease. TRIAL REGISTRATION: ClinicalTrials.gov, no. ISRCTN35739639.
Authors: Ramon Estruch; Miguel Angel Martínez-González; Dolores Corella; Jordi Salas-Salvadó; Valentina Ruiz-Gutiérrez; María Isabel Covas; Miguel Fiol; Enrique Gómez-Gracia; Mari Carmen López-Sabater; Ernest Vinyoles; Fernando Arós; Manuel Conde; Carlos Lahoz; José Lapetra; Guillermo Sáez; Emilio Ros Journal: Ann Intern Med Date: 2006-07-04 Impact factor: 25.391
Authors: Ramón Estruch; Emilio Ros; Jordi Salas-Salvadó; Maria-Isabel Covas; Dolores Corella; Fernando Arós; Enrique Gómez-Gracia; Valentina Ruiz-Gutiérrez; Miquel Fiol; José Lapetra; Rosa Maria Lamuela-Raventos; Lluís Serra-Majem; Xavier Pintó; Josep Basora; Miguel Angel Muñoz; José V Sorlí; José Alfredo Martínez; Miguel Angel Martínez-González Journal: N Engl J Med Date: 2013-02-25 Impact factor: 91.245
Authors: Dora Romaguera; Teresa Norat; Traci Mouw; Anne M May; Christina Bamia; Nadia Slimani; Noemie Travier; Herve Besson; Jian'an Luan; Nick Wareham; Sabina Rinaldi; Elisabeth Couto; Françoise Clavel-Chapelon; Marie-Christine Boutron-Ruault; Vanessa Cottet; Domenico Palli; Claudia Agnoli; Salvatore Panico; Rosario Tumino; Paolo Vineis; Antonio Agudo; Laudina Rodriguez; Maria Jose Sanchez; Pilar Amiano; Aurelio Barricarte; Jose Maria Huerta; Timothy J Key; Elisabeth A Spencer; H Bas Bueno-de-Mesquita; Frederike L Büchner; Philippos Orfanos; Androniki Naska; Antonia Trichopoulou; Sabine Rohrmann; Rudolf Kaaks; Manuela Bergmann; Heiner Boeing; Ingegerd Johansson; Veronica Hellstrom; Jonas Manjer; Elisabet Wirfält; Marianne Uhre Jacobsen; Kim Overvad; Anne Tjonneland; Jytte Halkjaer; Eiliv Lund; Toni Braaten; Dragun Engeset; Andreani Odysseos; Elio Riboli; Petra H M Peeters Journal: J Nutr Date: 2009-07-01 Impact factor: 4.798
Authors: Katherine Esposito; Maria Ida Maiorino; Giuseppe Bellastella; Demosthenes B Panagiotakos; Dario Giugliano Journal: Endocrine Date: 2016-07-09 Impact factor: 3.633
Authors: Pablo Pérez-Martínez; Dimitri P Mikhailidis; Vasilios G Athyros; Mónica Bullo; Patrick Couture; María I Covas; Lawrence de Koning; Javier Delgado-Lista; Andrés Díaz-López; Christian A Drevon; Ramón Estruch; Katherine Esposito; Montserrat Fitó; Marta Garaulet; Dario Giugliano; Antonio García-Ríos; Niki Katsiki; Genovefa Kolovou; Benoît Lamarche; Maria Ida Maiorino; Guillermo Mena-Sánchez; Araceli Muñoz-Garach; Dragana Nikolic; José M Ordovás; Francisco Pérez-Jiménez; Manfredi Rizzo; Jordi Salas-Salvadó; Helmut Schröder; Francisco J Tinahones; Rafael de la Torre; Ben van Ommen; Suzan Wopereis; Emilio Ros; José López-Miranda Journal: Nutr Rev Date: 2017-05-01 Impact factor: 7.110